<DOC>
	<DOCNO>NCT02127190</DOCNO>
	<brief_summary>This first-in-human ( FIH ) study CXA-10 . The main purpose trial demonstrate tolerability , safety pharmacokinetics ( PK ) CXA-10 various incremental dos , demonstrate safety tolerability rate emulsion vehicle infusion healthy volunteer . In addition , associate pharmacodynamic ( PD ) effect CXA-10 investigate .</brief_summary>
	<brief_title>Study CXA-10 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>1 . Male subject female subject nonchild bear potential age 18 50 year ( inclusive ) 2 . Females must child bear potential ( defined bilateral oophorectomy , hysterectomy , postmenopausal [ amenorrhea minimum 1 year postmenopausal status confirm follicle stimulate hormone ( FSH ) test ] ) . Female subject unable bear child ( e.g . tubal ligation , hysterectomy , postmenopausal ) must document case report form ( CRF ) . 3 . Body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) weight 60 kg 100 kg ( inclusive ) —Part A B 4 . BMI 30 50 kg/m2 subject Part C 5 . In good general health determine thorough medical history physical examination , ECG , vital sign , clinical laboratory evaluation . Results clinical laboratory test must without clinically significant abnormality , include hematology , clinical chemistry urinalysis . Subjects Part C may allow blood pressure reading to160/100 . 6 . Subjects must rest heart rate ( HR ) ≥50 beat per minute baseline 7 . QTcF interval ( Fredericia 's correction factor ) baseline ECG must ≤430 msec male ≤450 msec female screen predose . Subjects clinically relevant ECG parameter abnormality ( e.g. , PR interval , QRS deviation ) clinically significant ECG abnormality exclude study . Subjects history congenital long QT syndrome subject subject 's family exclude study ( see Section 6.4.3 . 8 . Adequate bilateral venous access allow repeat dose infusion blood sample 9 . Ability comprehend comply procedure 10 . Agree commit participate current protocol 11 . Provide write informed consent prior study procedure perform ( subject able understand inform consent form document subject require read ) 1 . Female subject pregnant lactate try conceive 2 . Female subject positive urine βhuman chorionic gonadotropin ( βhCG ) test screen Day 1 dose day 3 . Any clinically relevant abnormality identify screen history , physical laboratory examination , medical condition circumstance make volunteer unsuitable participation study 4 . Any clinical history cardiovascular event , arrhythmia , fainting , palpitation , personal family history congenital prolong QT syndromes 5 . History primary malignancy , include history melanoma suspicious undiagnosed skin lesion , exception basal cell squamous cell carcinoma skin cervical carcinoma situ malignancy curatively treat evidence disease least 5 year 6 . Past history pancreatitis 7 . History document hypersensitivity reaction egg egg product ( vehicle contain egg phospholipid ) 8 . History document hypersensitivity reaction soy soy product ( vehicle contain soy bean oil ) 9 . History regular alcohol consumption exceed 14 units/week woman 21 units/week men ( one unit = 125 mL wine 284 mL beer single 25 mL measure spirit ) within 6 month screen 10 . History smoking use nicotinecontaining product within past 6 month 11 . Treatment prescription nonprescription drug ( include vitamin , herbal dietary supplement ) within seven day five halflives , whichever longer , prior dose collection final PK sample . Use drug include aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) must avoid within 7 day prior first dose study interfere pharmacology CXA10 . Use high energy supplement drink ( especially , contain caffeine , protein supplement , weight loss drug ) smoke cessation product ( gum , inhaler , patch ) prohibit . Only acetaminophen permit dose 2 grams/day 12 . Sitting blood pressure &gt; 140 mmHg systolic and/or &gt; 90 mmHg diastolic 5 minute rest ( foot floor , arm hold level heart ) screen visit subject participate Parts A B . Subjects Part C may allow blood pressure read 160 mmHg systolic 100 mmHg diastolic 13 . Resting heart rate ≥100 beat per minute ( BPM ) 5 minute rest ( ) screen visit 14 . Any abnormality 12lead ECG screen include , limited follow PR interval &gt; 200 msec &lt; 120 msec Nonspecific intraventricular conduction delay ( IVCD ) QRS duration ≥110 msec morphology NOT meet criterion leave ( LBBB ) right bundle branch block ( RBBB ) Incomplete RBBB define QRS duration ≥100 msec &lt; 120 msec RBBB pattern Complete RBBB LBBB Evidence second third degree AV block Pathological Qwaves ( Qwave wider 0.04 sec depth great 0.40.5 mV ) Evidence ventricular preexcitation Evidence leave axis deviation ( left axis deviation 30 90 degree ) normal leftward axis , STT wave abnormality , LBBB and/or RBBB QTcF interval baseline ECG ≥430 msec male ≥450 msec female screen predose first dose session , clinically relevant ECG parameter ( e.g. , PR interval , QRS deviation ) abnormality 15 . Any cardiac murmur evident auscultation heart ( include evidence mitral valve prolapse ) 16 . A positive urine drug screen drug abuse , include alcohol positive urine cotinine ( ≥300 ng/mL cotinine ) screen visit entry clinic ( Note : urine cotinine require screening visit ) . 17 . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior begin screen period ( include investigational formulation market product , inhaled topical drug ) 18 . Blood collection great 500 mL within 56 day prior screen 19 . Seropositive human immunodeficiency virus ( HIV ) screen 20 . Positive Hepatitis B virus surface antigen ( HBsAg ) positive Hepatitis C virus antibody ( HCV Ab ) screen 21 . Any condition and/or situation cause Investigator deem subject unsuitable study ( e.g. , due expect study medication noncompliance , inability medically tolerate study procedure , subject 's unwillingness comply studyrelated procedure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>nitro-fatty acid</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>Nrf2 activation</keyword>
	<keyword>contrast induce AKI</keyword>
</DOC>